

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue **69.4m**
 Market Capitalisation **~\$34m**

BOARD & MANAGEMENT

Mr George Livery
 Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Stephen Thompson
 Executive Director

Mr Simon O'Loughlin
 Non-Executive Director

Mr Simon Taylor
 Non-Executive Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

Bod expands medicinal cannabis product suite following import of new cannabis extract

- **New cannabis extract to be supplied to a Lambert Initiative sponsored clinical trial relating to Tourette Syndrome**
- **Lambert Initiative is Australia's preeminent medicinal cannabis research group, focused on researching therapeutic uses of medicinal cannabis**
- **New product marks the fourth cannabis extract Bod has imported into Australia**
- **Sale of new extracts to generate revenues in the domestic market – Bod also pursuing commercial opportunities including product development and licencing**
- **Partnership with the Lambert Initiative provides considerable validation of the quality of MediCabilis™ cannabis extracts**
- **New extracts will be available via SAS Category B– marking the extension of Bod's medicinal cannabis product suite**

Sydney, Australia – 1 March 2019: Developer and distributor of natural, evidence-based skincare and health products including medicinal cannabis, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA) will begin supplying the Lambert Initiative with a pharmaceutical grade GMP produced cannabis extract for use in a clinical trial relating to Tourette Syndrome.

Bod has received its first order for a new cannabis extract containing THC and CBD from the Lambert Initiative, which it will supply immediately. This new extract will be used in a clinical trial relating to Tourette Syndrome, being undertaken in collaboration with Wesley Medical Research. The trial is being funded by the Lambert Initiative and external parties.

Tourette Syndrome is a neurological condition, characterised by repeated involuntary movements and uncontrollable sounds. It is lifelong condition and is thought to affect one in 100 school children. Should Bod's cannabis extracts have a positive effect on the condition, the Company will pursue commercial initiatives including product development and licencing.

Bod will commence importing this additional line extension under its medicinal cannabis import licence. The Company will make the new extract available to eligible patients and approved prescribers through Special Access Scheme Category B in the coming weeks. Bod is investigating other ways it can test the effect of this new cannabis extract on other conditions and will update shareholders as these progress.

The Lambert Initiative was established in 2015 following a \$33.7m donation from Barry and Joy Lambert to the University of Sydney to conduct high quality research to discover, develop and optimise safe and effective use of cannabinoid therapeutics in medicine.

The Lambert Initiative is actively advancing cannabis-based treatments into mainstream medicine. Supplying a high profile organisation provides considerable validation of Bod's cannabis extracts and is a testament to the Company's work in the cannabis sector.

Bod Australia CEO Jo Patterson said: “Collaborating and supplying an organisation of the Lambert Initiative's calibre is significant validation of Bod's product superiority and global uniqueness, as well as the Company's growing presence in the medicinal cannabis space.”

“To have our extracts utilised in an external clinical trial investigating the effects of medicinal cannabis in relation to Tourette Syndrome positions Bod exceptionally well for the future. Pending any successful results in relation to this specific condition, Bod will ensure the formulations are made available to eligible patient and approved prescribers under Special Access Scheme Category B. Further, Bod will ensure that it progresses any commercial opportunities which result from the trial, including product development and licencing.”

“The Board and management look forward to any ongoing collaborations with the Lambert Initiative. Bod will continue to support them with our unique cannabis extracts for their trials, and update shareholders as results are finalised .”

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is rapidly building an integrated cannabis business, underpinned by agreements with international counterparties Linnea SA, a leading Swiss botanicals extracts manufacturer and iX Biopharma Limited, a late stage Singapore-listed pharmaceutical company. Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia’s largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538